Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 1 of 1 for:    IgPro20_2001
Previous Study | Return to List | Next Study

Safety and Pharmacokinetics of IgPro20 and IgPro10 in Adults With Systemic Sclerosis (SSc)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04137224
Recruitment Status : Active, not recruiting
First Posted : October 23, 2019
Last Update Posted : April 3, 2020
Sponsor:
Information provided by (Responsible Party):
CSL Behring

Brief Summary:
This is a prospective, multicenter, randomized, open-label, crossover study to investigate the safety, tolerability, and pharmacokinetics of IgPro20 in subjects with diffuse cutaneous systemic sclerosis (dcSSc). The pharmacokinetic study aims to evaluate the relative bioavailability of IgPro20, and characterize pharmacokinetics of IgPro20 and IgPro10, respectively, in subjects with dcSSc. Safety, tolerability, and pharmacokinetics of IgPro10 will also be evaluated.

Condition or disease Intervention/treatment Phase
Diffuse Cutaneous Systemic Sclerosis Biological: IgPro20 Biological: IgPro10 Phase 2

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 26 participants
Allocation: Randomized
Intervention Model: Crossover Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: A Multicenter, Randomized, Open-label, Crossover, Phase 2 Study to Evaluate the Safety and Pharmacokinetics of IgPro20 (Subcutaneous Immunoglobulin, Hizentra®) and IgPro10 (Intravenous Immunoglobulin, Privigen®) in Adults With Systemic Sclerosis (SSc)
Actual Study Start Date : September 19, 2019
Estimated Primary Completion Date : August 2021
Estimated Study Completion Date : August 2021


Arm Intervention/treatment
Experimental: IgPro20
20% liquid formulation of human immunoglobulin for subcutaneous use
Biological: IgPro20
Human normal immunoglobulin for subcutaneous administration
Other Name: Hizentra

Experimental: IgPro10
10% liquid formulation of human immunoglobulin for intravenous use
Biological: IgPro10
Human normal immunoglobulin for intravenous administration
Other Name: Privigen




Primary Outcome Measures :
  1. Number of subjects with adverse events (AEs) for IgPro20 [ Time Frame: Up to 16 weeks ]
  2. Percentage of subjects with AEs for IgPro20 [ Time Frame: Up to 16 weeks ]
  3. Number and percentage of subjects with treatment emergent adverse events (TEAEs) for IgPro20 [ Time Frame: Up to 16 weeks ]
  4. Number and percentage of subjects with seriouis adverse events (SAEs) for IgPro20 [ Time Frame: Up to 16 weeks ]
  5. Number and percentage of subjects with adverse events of special interest (AESIs) for IgPro20 [ Time Frame: Up to 16 weeks ]
  6. Number of patients with AEs categorized as infusion site reactions (ISRs) for IgPro20 [ Time Frame: Up to 16 weeks ]
  7. Percentage of patients with AEs categorized as ISRs for IgPro20 [ Time Frame: Up to 16 weeks ]
  8. Rate of ISRs per subject for IgPro20 [ Time Frame: Up to 16 weeks ]
  9. Rate of ISRs per infusion for IgPro20 [ Time Frame: Up to 16 weeks ]
  10. Onset of ISRs for IgPro20 [ Time Frame: Up to 16 weeks ]
  11. Duration of ISRs for IgPro20 [ Time Frame: Up to 16 weeks ]

Secondary Outcome Measures :
  1. IgPro20 relative bioavailability (%F) [ Time Frame: Up to 16 weeks ]
  2. Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro20 [ Time Frame: Up to 240 hours after first infusion ]
  3. Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro20 [ Time Frame: Up to 240 hours after first infusion ]
  4. Maximum plasma drug concentration (Cmax) for IgPro20 [ Time Frame: Up to 240 hours after first infusion ]
  5. Minimum plasma drug concentration (Ctrough) for IgPro20 [ Time Frame: Prior to infusion ]
  6. Area under the concentration curve to the end of the dosing period (AUC0-tau) for IgPro10 [ Time Frame: Up to 672 hours after first infusion ]
  7. Area under the concentration curve up to the last measurable concentration (AUC0-last) for IgPro10 [ Time Frame: Up to 672 hours after first infusion ]
  8. Maximum plasma drug concentration (Cmax) for IgPro10 [ Time Frame: Up to 672 hours after first infusion ]
  9. Minimum plasma drug concentration (Ctrough) for IgPro10 [ Time Frame: Prior to infusion ]
  10. Number and percentage of subjects with AEs for IgPro10 [ Time Frame: Up to 16 weeks ]
  11. Number and percentage of subjects with treatment emergent adverse events (TEAEs) for IgPro10 [ Time Frame: Up to 16 weeks ]
  12. Number and percentage of subjects with seriouis adverse events (SAEs) for IgPro10 [ Time Frame: Up to 16 weeks ]
  13. Number and percentage of subjects with adverse events of special interest (AESIs) for IgPro10 [ Time Frame: Up to 16 weeks ]
  14. Number and percentage of subjects with AEs categorized as ISRs for IgPro10 [ Time Frame: Up to 16 weeks ]


Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age ≥ 18 years (male or female) at time of providing written informed consent
  • Documented diagnosis of systemic sclerosis (scleroderma) according to American College of Rheumatology (ACR) and European League Against Rheumatism (EULAR) criteria 2013 (diffuse cutaneous form of SSc).
  • Modified Rodnan Skin Score (mRSS) ≥ 15 and ≤ 45 at screening
  • Disease duration ≤ 5 years defined as the time from the first non-Raynaud's phenomenon manifestation
  • Capable of providing written informed consent and willing and able to adhere to all protocol requirements

Exclusion Criteria:

  • Primary rheumatic autoimmune disease other than dcSSc, including but not limited to rheumatoid arthritis, systemic lupus erythematosus, mixed connective tissue disorder, polymyositis, dermatomyositis, as determined by the investigator. Note: Subjects with fibromyalgia, secondary Sjogren's syndrome, and scleroderma-associated myopathy at screening are not excluded
  • Subject has mRSS > 2 at the potential subcutaneous (SC) infusion sites
  • History of skin condition precluding SC infusion, or clinical signs and symptoms of a chronic skin disease other than systemic sclerosis or skin manifestation of an allergic disease or other dermatological conditions that would interfere with trial assessments or compromise safety (eg, dermatitis, eczema, psoriasis)
  • Subject has clinical signs and symptoms of skin irritation (eg, pruritus, burning, erythema) or hypo/ hyperpigmentation (eg, scars, tattoos) at the potential SC infusion sites
  • Significant pulmonary arterial hypertension as documented by mean pulmonary arterial pressure > 30 mmHg on right heart catheterization requiring SC or IV prostacyclin or use of dual oral therapies
  • Forced vital capacity < 50% predicted or a diffusing capacity of the lung for carbon dioxide (DLCO) ≤ 40% predicted (corrected for hemoglobin)
  • A female who is pregnant, breastfeeding, or is a woman of childbearing potential who does not agree to use acceptable methods of contraception; a male who does agree to use acceptable methods of contraception.
  • Evidence of chronic kidney disease with an estimated glomerular filtration rate (eGFR) < 45 mL/min/1.73m2 or if subject is receiving dialysis. Subjects with current confirmed diagnosis of diabetes mellitus requiring medication with an eGFR < 90 ml/min/1.73m2

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04137224


Locations
Layout table for location information
Australia, South Australia
Royal Adelaide Hospital
Adelaide, South Australia, Australia, 5000
Australia, Victoria
St Vincent's Hospital
Melbourne, Victoria, Australia, 3065
France
Hôpital Cochin
Paris, France, 75014
Germany
Charité Universitätsmedizin Berlin
Berlin, Germany, 10117
Uniklinik Köln, innere Medizin
Köln, Germany, 50937
Krankenhaus St. Josef
Wuppertal, Germany, 42105
Italy
University of L'Aquila
L'Aquila, AQ, Italy, 67100
Università Politecnica delle Marche
Ancona, Italy, 60121
ASST Spedali Civili di Brescia
Brescia, Italy, 25123
AOU Careggi, Rheumatology Unit
Firenze, Italy, 50134
Azienda Ospedaliera Gaetano Pini
Milano, Italy, 20122
Poland
Uniwersytecki Szpital Kliniczny W Bialymstoku
Bialystok, Poland, 15-276
Szpital Kliniczny Jezus
Warsaw, Poland, 02-008
Narodowy Instytut Geriatrii
Warsaw, Poland, 02-637
United Kingdom
The Royal Free Hospital
London, United Kingdom, NW3 2QG
Sponsors and Collaborators
CSL Behring
Investigators
Layout table for investigator information
Study Director: Study Director CSL Behring
Layout table for additonal information
Responsible Party: CSL Behring
ClinicalTrials.gov Identifier: NCT04137224    
Other Study ID Numbers: IgPro20_2001
2018-003149-41 ( EudraCT Number )
First Posted: October 23, 2019    Key Record Dates
Last Update Posted: April 3, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: Yes
Plan Description:

CSL will consider requests to share Individual Patient Data (IPD) from systematic review groups or bona-fide researchers. For information on the process and requirements for submitting a voluntary data sharing request for IPD, please contact CSL at clinicaltrials@cslbehring.com.

Applicable country specific privacy and other laws and regulations will be considered and may prevent sharing of IPD.

If the request is approved and the researcher has executed an appropriate data sharing agreement, IPD that has been appropriately anonymized will be available.

Supporting Materials: Study Protocol
Statistical Analysis Plan (SAP)
Time Frame: IPD requests may be submitted to CSL no earlier than 12 months after publication of the results of this study via an article made available on a public website.
Access Criteria:

Requests may only be made by systematic review groups or bona-fide researchers whose proposed use of the IPD is non-commercial in nature and has been approved by an internal review committee.

An IPD request will not be considered by CSL unless the proposed research question seeks to answer a significant and unknown medical science or patient care question as determined by CSL's internal review committee.

The requesting party must execute an appropriate data sharing agreement before IPD will be made available.


Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by CSL Behring:
scleroderma
Additional relevant MeSH terms:
Layout table for MeSH terms
Scleroderma, Systemic
Scleroderma, Diffuse
Sclerosis
Pathologic Processes
Connective Tissue Diseases
Skin Diseases
Immunoglobulins, Intravenous
Immunologic Factors
Physiological Effects of Drugs